Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 9/20 | 0.36 |
| ▸ | RAF1 | P04049 | 3/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 7/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11029321 | 0.91 | IDH1 (0.43) | IDH1BRAFRAF1DDR2EGFR | |
| SCHEMBL11031849 | 0.89 | IDH1 (0.40) | IDH1BRAFRAF1DDR2EGFR | |
| SCHEMBL1160958 | 0.89 | IDH1 (0.47) | IDH1BRAFRAF1DDR2EGFR | |
| SCHEMBL12873243 | 0.89 | AURKA (0.42) | IDH1BRAFRAF1DDR2EGFR | |
| SCHEMBL1160828 | 0.86 | DDR2 (0.40) | IDH1BRAFRAF1DDR2EGFR | |
| SCHEMBL1160825 | 0.85 | FGFR2 (0.43) | IDH1BRAFRAF1DDR2MEN1 | |
| SCHEMBL1161279 | 0.82 | BRAF (0.39) | BRAFRAF1EGFR | |
| SCHEMBL1160806 | 0.82 | BRAF (0.41) | BRAFRAF1EGFR | |
| SCHEMBL1160800 | 0.82 | BRAF (0.40) | BRAFRAF1EGFR | |
| SCHEMBL11031834 | 0.81 | MMP14 (0.37) | BRAFRAF1EGFRMMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011017142-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | IDH1 747/4885BRAF 582/4885RAF1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.